Co Diagnostics Stock Performance
| CODX Stock | USD 2.22 0.11 4.72% |
The firm owns a Beta (Systematic Risk) of 2.11, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Co Diagnostics will likely underperform. At this point, Co Diagnostics has a negative expected return of -1.76%. Please make sure to confirm Co Diagnostics' information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if Co Diagnostics performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Co Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (0.85) | Five Day Return (1.27) | Year To Date Return (58.09) | Ten Year Return (98.66) | All Time Return (98.66) |
Last Split Factor 1:30 | Last Split Date 2026-01-02 |
1 | What to Expect from Co-Diagnosticss Earnings | 11/12/2025 |
2 | Disposition of 57499 shares by Nelson James B of Co Diagnostics subject to Rule 16b-3 | 11/21/2025 |
3 | Acquisition by Murphy Edward L. of 57499 shares of Co Diagnostics subject to Rule 16b-3 | 11/24/2025 |
4 | Financial Review Co-Diagnostics versus AMN Healthcare Services | 11/25/2025 |
5 | CoDiagnostics Upgraded to Buy Heres What You Should Know | 12/02/2025 |
6 | Co-Diagnostics, Arabian Eagle to Develop and Commercialize Co-Dx Tech - Medical Product Outsourcing | 12/12/2025 |
7 | Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India | 12/18/2025 |
8 | Co-Diagnostics Announces Reverse Stock Split | 12/30/2025 |
9 | Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships | 01/12/2026 |
10 | Co-Diagnostics, Inc. Receives Consensus Rating of Hold from Brokerages | 01/15/2026 |
11 | Co-Diagnostics Faces Nasdaq Delisting After Failing to Meet Minimum Bid Price - AD HOC NEWS | 01/26/2026 |
12 | Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro Instrument | 02/05/2026 |
| Begin Period Cash Flow | 14.9 M | |
| Total Cashflows From Investing Activities | 17.1 M |
Co Diagnostics Relative Risk vs. Return Landscape
If you would invest 1,181 in Co Diagnostics on November 11, 2025 and sell it today you would lose (948.00) from holding Co Diagnostics or give up 80.27% of portfolio value over 90 days. Co Diagnostics is currently does not generate positive expected returns and assumes 11.3741% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than CODX, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Co Diagnostics Target Price Odds to finish over Current Price
The tendency of CODX Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.22 | 90 days | 2.22 | more than 93.0 |
Based on a normal probability distribution, the odds of Co Diagnostics to move above the current price in 90 days from now is more than 93.0 (This Co Diagnostics probability density function shows the probability of CODX Stock to fall within a particular range of prices over 90 days) .
Co Diagnostics Price Density |
| Price |
Predictive Modules for Co Diagnostics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Co Diagnostics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Co Diagnostics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Co Diagnostics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Co Diagnostics is not an exception. The market had few large corrections towards the Co Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Co Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Co Diagnostics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.86 | |
β | Beta against Dow Jones | 2.11 | |
σ | Overall volatility | 3.50 | |
Ir | Information ratio | -0.16 |
Co Diagnostics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Co Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Co Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Co Diagnostics generated a negative expected return over the last 90 days | |
| Co Diagnostics has high historical volatility and very poor performance | |
| Co Diagnostics has high likelihood to experience some financial distress in the next 2 years | |
| Co Diagnosticshas 2,252,057 shares shorted by Co Diagnostics investors is about 100% of outstending shares | |
| The company reported the previous year's revenue of 3.92 M. Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 172.84 K. | |
| Co Diagnostics currently holds about 86.49 M in cash with (29.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Co Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro Instrument |
Co Diagnostics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CODX Stock often depends not only on the future outlook of the current and potential Co Diagnostics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Co Diagnostics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1 M | |
| Cash And Short Term Investments | 29.7 M |
Co Diagnostics Fundamentals Growth
CODX Stock prices reflect investors' perceptions of the future prospects and financial health of Co Diagnostics, and Co Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CODX Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (48.24) % | ||||
| Current Valuation | (5.09 M) | ||||
| Shares Outstanding | 2.1 M | ||||
| Price To Earning | 6.78 X | ||||
| Price To Book | 0.12 X | ||||
| Price To Sales | 9.61 X | ||||
| Revenue | 3.92 M | ||||
| Gross Profit | 172.84 K | ||||
| EBITDA | (38.7 M) | ||||
| Net Income | (37.64 M) | ||||
| Cash And Equivalents | 86.49 M | ||||
| Cash Per Share | 2.80 X | ||||
| Total Debt | 2.15 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 16.95 X | ||||
| Book Value Per Share | 24.82 X | ||||
| Cash Flow From Operations | (29.16 M) | ||||
| Earnings Per Share | (29.40) X | ||||
| Market Capitalization | 4.88 M | ||||
| Total Asset | 64 M | ||||
| Retained Earnings | (33.04 M) | ||||
| Working Capital | 24.98 M | ||||
| Current Asset | 858.78 K | ||||
| Current Liabilities | 2.84 M | ||||
About Co Diagnostics Performance
Evaluating Co Diagnostics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Co Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Co Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 450.67 | 428.14 | |
| Return On Tangible Assets | (0.89) | (0.94) | |
| Return On Capital Employed | (0.64) | (0.60) | |
| Return On Assets | (0.53) | (0.56) | |
| Return On Equity | (0.62) | (0.65) |
Things to note about Co Diagnostics performance evaluation
Checking the ongoing alerts about Co Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Co Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Co Diagnostics generated a negative expected return over the last 90 days | |
| Co Diagnostics has high historical volatility and very poor performance | |
| Co Diagnostics has high likelihood to experience some financial distress in the next 2 years | |
| Co Diagnosticshas 2,252,057 shares shorted by Co Diagnostics investors is about 100% of outstending shares | |
| The company reported the previous year's revenue of 3.92 M. Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 172.84 K. | |
| Co Diagnostics currently holds about 86.49 M in cash with (29.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Co Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro Instrument |
- Analyzing Co Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Co Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Co Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Co Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Co Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Co Diagnostics' stock. These opinions can provide insight into Co Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.